Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Biotechnology

Healthcare
$61.99 -1.39%

-$0.46 today

Market cap
$1.79B
Beta
0.89
P/E (TTM)
-597.6
EPS (TTM)
-$0.05
52W Low $13.09High $35.66

Volume 0.48M

Average 0.43M

ETON Pre-Tax Margin

Income before tax as a percentage of revenue.

Eton Pharmaceuticals, Inc.NASDAQ: ETON

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to 6.5%

Pre-tax margin was 6.5% in Q1 FY2026, up 15.2 pp from a year earlier. On a trailing-twelve-month basis it was -1.7%, up 7.6 pp year over year. Over 3 fiscal years it widened by 36.7 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
6.5%-0.2 pp QoQ
Last fiscal yearDec 2025
-5.7%+4.1 pp YoY
LTMMar 2026
-1.7%+7.6 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+15.2 pp——
1 year+4.1 pp——
3 years+36.7 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-5.7%
Year-over-year change
+4.1pp

Pre-Tax Margin vs competitors

How ETON compares with its peers on the latest reported figures

  • ETON's LTM Mar 2026 pre-tax margin of -1.7% is the 3rd highest of the 8 companies compared; the peer median is -24.5%.
  • Its year-over-year change of +7.6 pp is the 4th highest of 8, against a peer median of +6.5 pp.
  • Over three fiscal years its change of +36.7 pp compares with a peer median of +292.5 pp.
ETON Competitors Peer median
Pre-Tax Margin for ETON and competitors
Company Period LTM level YoY 3-year change
ZVRAZevra Therapeutics, Inc.LTM Mar 2026109.1% +294.8 pp+345.2 pp
PHARPharming Group N.V.LTM Mar 20265.4% +6.5 pp-3.9 pp
ETONEton Pharmaceuticals, Inc.LTM Mar 2026-1.7% +7.6 pp+36.7 pp
FENCFennec Pharmaceuticals Inc.LTM Mar 2026-16.2% +29.3 pp+1523.3 pp
TVTXTravere Therapeutics, Inc.LTM Sep 2026-24.5% -4.2 pp+292.5 pp
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-37.5% +530.6 pp+73239.9 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-56.7% -29.9 pp+3.7 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-90.5% +2.2 pp+108.3 pp
DMACDiaMedica Therapeutics Inc.FY2025— ——
LRMRLarimar Therapeutics, Inc.FY2025— ——
Peer median (excluding ETON) -24.5%+6.5 pp+292.5 pp

Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.83M21.25M31.64M39.01M79.95M
Cost of Revenue2.62M6.93M10.58M15.6M37.21M
Gross Profit19.21M14.32M21.06M23.41M42.74M
Gross Margin88.0%67.4%66.6%60.0%53.5%
Research & Development6.24M4M3.32M3.26M7.77M
Selling, General & Admin14.47M18.58M18.93M22.75M35.82M
Operating Expenses20.7M22.58M22.25M26.01M42.67M
Depreciation & Amortization462K1.77M901K1.15M4.04M
EBITDA(1.49M)(7.25M)212K(657K)4.27M
EBITDA Margin-6.8%-34.1%0.7%-1.7%5.3%
Operating Income(1.5M)(8.26M)(1.19M)(2.6M)72K
Operating Margin-6.8%-38.9%-3.8%-6.7%0.1%
Interest Income00000
Interest Expense1.04M955K1.06M2.01M4.78M
Other Income / Expenses(460K)(761K)503K(1.21M)(4.63M)
Income Before Tax(1.96M)(9.02M)(689K)(3.81M)(4.56M)
Pre-Tax Margin-9.0%-42.4%-2.2%-9.8%-5.7%
Income Tax Expense00247K15K43K
Net Income(1.96M)(9.02M)(936K)(3.82M)(4.6M)
Net Margin-9.0%-42.4%-3.0%-9.8%-5.8%
EPS (Basic)(0.08)(0.36)(0.04)(0.15)(0.17)
EPS (Diluted)(0.08)(0.36)(0.04)(0.15)(0.17)
Weighted Avg Shares25.21M25.15M25.65M25.9M26.91M
Weighted Avg Shares (Diluted)25.21M25.15M25.65M25.9M26.91M

Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Intrinsic Alpha fair value

Locked

Current Price

$61.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.